- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Antisense oligonucleotide therapeutic approach for Timothy syndrome ; volume:628 ; number:8009 ; day:24 ; month:4 ; year:2024 ; pages:818-825 ; date:4.2024
Nature; 628, Heft 8009 (24.4.2024), 818-825, 4.2024
- Urheber
-
Chen, Xiaoyu
Birey, Fikri
Li, Min-Yin
Revah, Omer
Levy, Rebecca
Thete, Mayuri Vijay
Reis, Noah
Kaganovsky, Konstantin
Onesto, Massimo
Sakai, Noriaki
Hudacova, Zuzana
Hao, Jin
Meng, Xiangling
Nishino, Seiji
Huguenard, John
Pașca, Sergiu P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41586-024-07310-6
- URN
-
urn:nbn:de:101:1-2407180747048.758873341379
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Xiaoyu
- Birey, Fikri
- Li, Min-Yin
- Revah, Omer
- Levy, Rebecca
- Thete, Mayuri Vijay
- Reis, Noah
- Kaganovsky, Konstantin
- Onesto, Massimo
- Sakai, Noriaki
- Hudacova, Zuzana
- Hao, Jin
- Meng, Xiangling
- Nishino, Seiji
- Huguenard, John
- Pașca, Sergiu P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Nonviral delivery systems for antisense oligonucleotide therapeutics
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Nonviral delivery systems for antisense oligonucleotide therapeutics
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Nonviral delivery systems for antisense oligonucleotide therapeutics
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases